Kei Kishimoto
Selecta Biosciences (United States)(US)
Publications by Year
Research Areas
Inflammatory Bowel Disease, Immune Response and Inflammation, Immunotherapy and Immune Responses, Helicobacter pylori-related gastroenterology studies, Virus-based gene therapy research
Most-Cited Works
- → Efficacy and safety of a humanized α4β7 antibody in active crohn's disease (CD)(2003)44 cited
- → Second-Generation Lymphocyte Function-Associated Antigen-1 Inhibitors: 1H-Imidazo[1,2-α]imidazol-2-one Derivatives(2004)34 cited
- → SAT0402 SEL-212 PHASE 2 CLINICAL STUDY IN SYMPTOMATIC GOUT PATIENTS: IMMTOR TOLEROGENIC NANOPARTICLES COMBINED WITH PEGADRICASE MITIGATES IMMUNOGENICITY AND ENABLES SUSTAINED REDUCTION OF SERUM URIC ACID LEVELS, LOW RATE OF GOUT FLARES AND MONTHLY DOSING(2019)6 cited
- → A RANDOMIZED CONTROLLED TRIAL OF A HUMANIZED ALPHA4BETA7 ANTIBODY IN ULCERATIVE COLITIS (UC)(2003)5 cited
- → These Abstracts Were Submitted to the AGA in mid-April, Selected by the AGA Council, and Presented During DDW 2003 in Orlando, Florida(2003)1 cited
- → Adjuvant-carrying targeted Synthetic Vaccine Particles ( t SVP™) augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release (75.3)(2012)
- → Long-term CTL induction and therapeutic tumor suppression by antigen- and adjuvant-carrying polymer nanoparticles(2013)
- → Re-dosing AAV gene therapy vectors - the elephant in the room(2018)